| abstract |
The present invention relates to a fusion protein dimer including glucagon-like peptide-1 (GLP-1) and interleukin-1 receptor antagonist (IL-1Ra) and a pharmaceutical composition using same for treating metabolic diseases. In addition to acting significantly as a GLP-1 hormone, the fusion protein dimer was also identified to bind effectively to an IL-1 receptor to excellently inhibit the signaling to IL-1β produced by inflammasome. Therefore, the fusion protein dimer according to the present invention exhibits the efficacies of GLP-1 and IL-1 receptor antagonist in combination and as such, can be utilized for treating and preventing metabolic diseases such as diabetes mellitus, obesity, and hyperlipidemia, finding high industrial applicability. |